Grant Details

GRANT OVERVIEW

Grant name and funding organization

Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)

National Institutes of Health (NIH)

Total funding amount and duration

Direct costs of up to $450,000 for a maximum project period of three years.

Primary objective and mission statement

To support formative research, intervention development, and pilot-testing of interventions targeting HIV prevention and treatment for individuals who use drugs.

Key stakeholders and beneficiaries

Individuals who use substances, healthcare providers, and organizations involved in HIV prevention and treatment.

ELIGIBILITY CRITERIA

Organization Requirements

Eligible organization types include higher education institutions, nonprofits, for-profit organizations, local governments, state governments, and federal agencies.

Foreign organizations are also eligible to apply.

Geographic Scope

Applications from U.S. and non-U.S. entities are accepted.

Project Requirements

Focus on formative research, intervention development, and pilot-testing of interventions for HIV prevention and treatment.

Interventions may include behavioral, social, or structural approaches.

Financial Requirements

Direct costs may not exceed $450,000 over three years, with no more than $225,000 in any single year.

Timeline Requirements

Applications are due by May 7, 2027, with an opening date for submissions on April 7, 2025.

Previous Funding Considerations

No restrictions on prior grant funding mentioned.

APPLICATION PROCESS

Required documentation and materials

Applications must follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide.

Evaluation criteria and scoring system

Applications will be evaluated based on scientific and technical merit, including significance, innovation, and approach.

Review process and timeline

Applications will undergo peer review and may receive a second level of review by the appropriate national Advisory Council or Board.

Selection criteria and priorities

Scientific and technical merit, availability of funds, and relevance to program priorities will be considered.

SPECIAL CONSIDERATIONS

Unique aspects or requirements

Engagement of end users in the research process is emphasized.

Potential challenges or limitations

Applications focusing solely on the development of intervention protocols without testing will not be reviewed.

Strategic alignment opportunities

Applicants are encouraged to consult NIH HIV priorities and NIDA's HIV priorities.

Competitive advantages or disadvantages

Strong evidence of capability to conduct the proposed study is encouraged.

KEY INSIGHTS AND RECOMMENDATIONS

Critical success factors

Engagement of relevant end users and a well-supported theory of change are critical.

Common pitfalls to avoid

Avoid applications that do not integrate substance use into study aims.

Strategic recommendations for applicants

Provide strong evidence of resources and experience in conducting related studies.

Competitive positioning advice

Highlight unique aspects of the proposed intervention and its relevance to current HIV challenges.

Grant Details

hiv substance use healthcare clinical trials public health intervention development treatment prevention research drug abuse community engagement
Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
PAR-24-329
National Institutes of Health (NIH)
EDU NGO PUBLIC RESEARCH SME OTHER
US
HEALTHCARE SOCIAL
DEVELOPMENT
0-10 11-50 51-250 251-500 500+
SDG3
FUNDING RESEARCH_DEVELOPMENT
None
450000.00
None
450000.00
USD
None
May 8, 2027, 10 p.m.
Not specified